FDA Panel Rejects OTC Drug An FDA advisory panel rejects Merck's proposal to sell a cholesterol-lowering drug without a prescription. The FDA complained that a proposed label for the product is not informative enough, and that an OTC statin might create false confidence in consumers. NPR's Allison Aubrey reports.
NPR logo

FDA Panel Rejects OTC Cholesterol Drug

  • Download
  • <iframe src="https://www.npr.org/player/embed/4285604/4285605" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
FDA Panel Rejects OTC Cholesterol Drug

FDA Panel Rejects OTC Cholesterol Drug

FDA Panel Rejects OTC Cholesterol Drug

  • Download
  • <iframe src="https://www.npr.org/player/embed/4285604/4285605" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

An FDA advisory panel rejects Merck's proposal to sell a cholesterol-lowering drug without a prescription. The FDA complained that a proposed label for the product is not informative enough, and that an OTC statin might create false confidence in consumers. NPR's Allison Aubrey reports.